Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|June 10, 2024

Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management

Author(s)Kristine Kucera, PA-C, MPAS, DHS , Mickey Bryson

Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Episodes in this series

Video 1 - "Creating a Connection: First Appointment Insights and Critical Inquiries Providers Should Make"

EP. 1 Creating a Connection: First Appointment Insights and Critical Inquiries Providers Should Make

Video 2 - "Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management" - 2 KOLs in this video.

EP. 2 Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management

EP. 3 The Road to Relief: Navigating a Personal Atopic Dermatitis Journey

EP. 3 The Road to Relief: Navigating a Personal Atopic Dermatitis Journey

Video 3 - featuring 2 panelists in, "Navigating Treatment Challenges: Addressing Negative Responses and Determining the Next Course of Action "

EP. 4 Navigating Treatment Challenges: Addressing Negative Responses and Determining the Next Course of Action

Video 2 - featuring 2 panelists in, "Empowering Patients: Understanding New Treatments and Long-Term Considerations with Fresh Approaches and FDA Endorsements "

EP. 5 Empowering Patients: Understanding New Treatments and Long-Term Considerations with Fresh Approaches and FDA Endorsements

Video 5 - featuring 2 panelists in, "Quality of Life + Closing Thoughts

EP. 6 Quality of Life + Closing Thoughts

EP. 7 Navigating a Long-Term Journey: From Topicals to Systemic Therapies in AD

EP. 7 Navigating a Long-Term Journey: From Topicals to Systemic Therapies in AD

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Phase 2 Data Highlight Roflumilast Cream in Infant AD

ByMaddi Hebebrand, MC, Associate Editor

February 2nd 2026

Kyowa Kirin Takes Full Control of Rocatinlimab Program

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Phase 2 TYK2 Inhibition Shows Promise in AD

ByMaddi Hebebrand, MC, Associate Editor

January 30th 2026

Steroid Stewardship during Infant Flare

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 28th 2026

Case Study 2: Managing Severe Infant Flares

ByAdam Friedman, MD, FAAD,Lawrence Eichenfield, MD,Alexandra K. Golant, MD

January 28th 2026

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect